Genetics

Rare Disease Genetic Testing Market To Account To Grow At A CAGR Of 8.30% In The Forecast Period Of 2020 To 2027 | Leading Players- Quest Diagnostics,…

The universal Rare Disease Genetic Testing Market report conveys in-depth market study and future prospects of the Rare Disease Genetic Testing industry. Furthermore, the market report gives all the CAGR projections of the historic year 2018, base year 2019, and estimate time of 2020 2027. The market study and analysis of this report also lends a hand to figure out types of consumers, their views about the product, their buying intentions and their ideas for advancement of a product. This credible Rare Disease Genetic Testing Market report has been prepared with the thorough market analysis carried out by a team of industry experts, dynamic analysts, skilful forecasters and well-informed researchers.

Summary of the Report

Rare disease genetic testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.30% in the above-mentioned forecast period. The increase in the facilities for patients affected by rare diseases has been directly impacting the growth of rare disease genetic testing market.

Get Free Sample Copy of the Report to understand the structure of the complete report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-rare-disease-genetic-testing-market

Major Key Players of the Rare Disease Genetic Testing Market

Quest Diagnostics, Inc., Centogene N.V., Eurofins Scientific, Strand Life Sciences, Ambry Genetics, PerkinElmer, Inc., Macrogen, Inc., Baylor Genetics, Color, Health Network Laboratories, L.P., Preventiongenetics, Progenity, Inc., Invitae Corporation, 3billion, Inc., Arup Laboratories, Coopersurgical, Inc., Fulgent Genetics, Myriad Genetics, Inc., Laboratory Corporation Of America Holdings and Opko Health, Inc., among other domestic and global players.

GlobalRare Disease Genetic TestingMarket Scope and Market Size

Rare disease genetic testing market is segmented on the basis of disease type, technology, specialty and end use. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Check Table of Contents of This Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-rare-disease-genetic-testing-market

Geographical Coverage of Rare Disease Genetic Testing Market

Key insights from COVID-19 impact analysis:

Table of Contents

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert@https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-rare-disease-genetic-testing-market

Key Pointers of the Report

Additional Pointers of the Report:

Given below are some of the added key points of the report:

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates.

Contact Us:

Data Bridge Market Research

Tel: +18883872818

corporatesales@databridgemarketresearch.com

Read the original here:
Rare Disease Genetic Testing Market To Account To Grow At A CAGR Of 8.30% In The Forecast Period Of 2020 To 2027 | Leading Players- Quest Diagnostics,...

Genetics

Increasing Government Investments and Favorable Policies to Aid the Growth of the Predictive Genetic Testing Market 2019 2029 – Eurowire

The global Predictive Genetic Testing market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Predictive Genetic Testing market along with the estimated trajectory of the market over the course of the stipulated timeframe.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Predictive Genetic Testing market.

Enticing discounts for new market players! Offer expires soon!

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

Segmentation analysis

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

The report ponders over the market scenario in various geographies and highlights the major opportunities, trends, and challenges faced by market players in each region. An in-depth country wise analysis of each major region provides readers a deep understanding of the regional aspects of the market including, the market share, pricing analysis, revenue growth, and more.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

The market report on the Predictive Genetic Testing market addresses some important questions such as:

Crucial data enclosed in the report:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

About us:

PMR is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

305 Broadway, 7th Floor

New York City, NY 10007

United States

Ph.no. +1-646-568-7751

E-mail id- [emailprotected]

Website: https://www.persistencemarketresearch.co

See the original post here:
Increasing Government Investments and Favorable Policies to Aid the Growth of the Predictive Genetic Testing Market 2019 2029 - Eurowire

Cell Biology

Cell-Free Technology Comes Of Age: BioBits Is Changing The Way We Teach Biology – Forbes

BioBits kits are designed to be used by students and teachers with no biological training. They use ... [+] simple, hands-on experiments, to teach concepts of synthetic and molecular biology. Credit: Wyss Institute at Harvard University (https://wyss.harvard.edu/news/biobits-new-biology-kits-for-a-new-generation-of-kids/)

Hundreds of AP (Advanced Placement) Biology students across eight Boston public schools could be finding a silver lining in online high school. Thanks to a grant from the Massachusetts Life Sciences Center, their curriculum now includes cutting-edge, hands-on biotechnology kits that are being delivered to their doorstep.

Born from a collaboration between MIT and Northwestern University, BioBits is the latest product by miniPCR bio, which specializes in making low-cost biotech equipment for students and scientists alike. Realizing the drastic need for online methods of instruction, they partnered with Mass Insight to develop a BioBits take-home lab activity that teaches AP biology students the central dogma of biology: transcription and translation.

As schools continue to be closed, one thing is increasingly clear: online instruction is hard, not just for students, but also for educators. They are away from their usual workplace. They only interact with the kids through screens. They have very limited opportunities for meaningful engagement and all of a sudden, you open up this little box full of biology, says Sebastian Kraves, Co-Founder of miniPCR.

The safety and accessibility of BioBits is hard to beat. Biology is an expensive field to dabble in, but $100 is enough to provide a classrooms worth of BioBits kits. Since there are no live organisms like bacteria, expensive equipment necessary for the most basic biology lab freezers, incubators, and sterile tools are no longer a limiting factor.

Freeze-dried cell extracts are shelf-stable and can ship worldwide. In the past few months, BioBits kits have been delivered to places outside the United States such as Denmark, Indonesia, and Chile - just to name a few.

Starting next year, they will even make their way to the International Space Station. MiniPCR and Boeing manage the annual Genes in Space challenge, where students will soon be able to submit BioBits experiment ideas, one of which will be selected for an astronaut to conduct on board the ISS.

While the science lesson in these kits is simple: cells make proteins from genes, it begs another question: how is this possible without the living cell itself?

Teachers will stop me and say, wait, wait, I get transcription and translation. But tell me more about that cell-free technology. I didn't realize you could do that, Ally Huang recalls. She and Jessica Stark made the concept of the synthetic biology educational kit a reality during their graduate studies at MIT and Northwestern, respectively.

The core breakthrough is cell-free technology. While it has been used for applications ranging from diagnostics to manufacturing, the way it is making its way into the classroom is a subtle but important shift.

If cell-free technology is robust, safe, and cheap enough for students to tinker with, it could be coming out of lag phase into its exponential growth of potential applications, suggests Dr. Mike Jewett, Professor of Chemical and Biological Engineering at Northwestern.

While the field is still young, substantial effort is being made to increase diversity and equity. This could be one place where synthetic biology could truly embody the values of the twenty-first century.

There's really great research that shows that engagement with science early in a student's career and in meaningful hands-on ways is a great way to get students interested in science. And so I would hope that BioBits and other hands-on activities can be implemented in schools to encourage people from all different backgrounds to pursue careers in STEM, Jessica emphasizes.

The personal backgrounds of the eclectic team behind BioBits shows just how much of an impact access could make.

BioBits kits are designed so that students and teachers with no previous biological training can ... [+] perform their own genetic experiments without the need for expensive and bulky lab equipment, at a fraction of the cost. Credit: Megan Beltran (https://phys.org/news/2018-08-biobits-synthetic-biology-k-students.html)

My favorite gift as a kid was a chemistry kit that I got from my grandmother in the very early 70s, Dr. Jim Collins reminisces. Hes now a Professor of Bioengineering at MIT.

And as a parent of two college-age kids, both interested in science. I introduced them to the chemistry kits, I got the electronic kits, I got the robotic kits, and was really disappointed that there was nothing biological that could be acquired.

Professor Jewett was drawn into biology through the chemistry behind living systems. Ally was fascinated by a fetal pig dissection in high school. Jessica, by the idea that tiny proteins operate every function inside a cell.

Sebastian got a copy of The Voyage of the Beagle from his grandmother at age 12. I did not have any hands on labs. I barely had any science classes. My high school back in Argentina was very resource limited, and also very social sciences oriented. And I went on to study economics. With BioBits, Sebastian is determined to change that narrative.

In sharp contrast to the breakneck increase in our ability to engineer biology, biology education has not changed for generations until, perhaps, now.

Im the founder of SynBioBeta, and some of the companies that I write about are sponsors of the SynBioBeta conference andweekly digest. Thank you toDesiree Hofor additional research and reporting in this article.

See original here:
Cell-Free Technology Comes Of Age: BioBits Is Changing The Way We Teach Biology - Forbes

Cell Biology

Researchers hope to harness the power of llama nanobodies to treat and prevent COVID-19 – FOX43.com

Llama nanobodies are surprisingly effective at neutralizing the virus, said researchers at the University of Pittsburgh School of Medicine.

PITTSBURGH An unlikely hero has emerged as a potential ally in the fight against COVID-19. Researchers at UPMC are seeing hope for a coronavirus treatment in tiny llama antibodies.

These llama antibodies are called nanobodies and they are much smaller than human antibodies. Their tiny stature gives them the unique ability to latch onto the coronavirus spike protein, blocking the virus from infecting cells.

Dr. Yi Shi, assistant professor of cell biology at the University of Pittsburgh School of Medicine, turned to a llama named Wally to generate these nanobodies. He said they are surprisingly effective at neutralizing the virus.

What we did was we immunized llama Wally with the virus spike protein. Then, it took about 50 to 55 days for Wally to develop nanobodies that can bind very tightly to this virus spike protein, explained Dr. Shi.

Using a mass spectrometry-based technique that Dr. Shi has been perfecting for the past three years, he and his lab team identified the nanobodies in Wallys blood that bind to SARS-CoV-2 most strongly, preventing its spread to cells.

Nanobodies are very stable and potentially could be stored for a long time after production. They can also be delivered by an inhaler directly to the lungs, which makes them particularly promising for respiratory infections such as COVID-19, according to the National Institutes of Health.

Traditional SARS-CoV-2 antibodies require an IV, which dilutes the product throughout the body, necessitating a much larger dose and costing patients and insurers around $100,000 per treatment course, said Dr. Shi.

Dr. Shi said his nanobodies taken from Wally can sit at room temperature for six weeks and can be administered to people via an inhaler or nasal spray to treat or prevent COVID-19. Since SARS-CoV-2 is a respiratory virus, the nanobodies could find and latch onto it in the respiratory system, before it even has a chance to do damage.

I think it is mostly effective for early stage treatment, Dr. Shi added. Basically, preventing the disease from a mild stage to the severe disease.

Dr. Shi said Wally was not harmed during the pre-clinical study. Owners on his farm in Minnesota said Wally is doing great with his llama friends, always coming to greet people when they enter his pen.

Researchers have a long way to go before any treatments are ready for public use. Dr. Shi is hoping to garner enough support to finalize their pre-clinical studies and begin clinical trials for testing.

Link:
Researchers hope to harness the power of llama nanobodies to treat and prevent COVID-19 - FOX43.com

Cell Biology

Brain Development and Disorder Research Receives $1.5 Million NSF Boost – USC Viterbi School of Engineering

A 15-day-old brain organoid: Department of Biomedical Engineering researchers are partnering with Keck School of Medicine of USC to improve the creation of these materials, which can help us better understand brain development and disorders.Image/ Giorgia Quadrato

The human brain is an incredibly complex organ to study in its living tissue form. Researchers cannot experiment on human tissue directly, and animal models are often too different to human physiology to be effective.

For this reason, in the last decade, neurological research has been increasingly turning to brain-on-a-chip organoid models to give researchers living examples to demonstrate brain development, and how to effectively treat brain diseases and disorders. Organoids are grown out of stem cells into new cell clusters that mimic the structure of and features of a whole organ, such as the brain.

Co-principal investigator Megan McCain from the USC Viterbi Department of Biomedical Engineering will partner with fellow co-principal investigators Giorgia Quadrato and Leonardo Morsut in the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC on a four year, $1.5m NSF-funded project to vastly improve the process of developing brain organoids. The project aims to make the end products more consistent and reliable as tools for brain researchers.

McCain is the Chonette Early Career Chair and assistant professor of biomedical engineering at USC Viterbi. She said that one of the biggest hurdles in the current process of organoid creation was their lack of uniformity.

Researchers start with a small group of human stem cells, and then give them some chemical cues to direct their development into brain tissue, but ultimately, the cells are mostly left to their own devices, so they often grow very randomly, McCain said. They divide and differentiate into other cell types in a somewhat haphazard process. So if you make ten organoids, all ten of them will look slightly different.

A brain organoid in a fluidic device from the labs of Megan McCain and Giorgia Quadrato.

McCain said it was this issue that could be detrimental to the accuracy of using organoids in certain types of research, such as the testing of therapeutics and how the brain responds to these drugs, and that organoids needed to be more uniform and reproducible in order to be more effective tools.

Drug testing with organoids today is very challenging because it is hard to separate the effect of the drug from the inherent variability of the organoids themselves, McCain said.

Morsut said that his part of the project involves developing synthetic molecular tools to simplify the analysis of what happens during the formation of brain organoids in a laboratory setting.

The normal molecules that are used by the cells to self-organize, as well as to make decisions, are linked in very complex networks, and we need artificial tools to tease apart the contributions of these different components, Morsut said. The challengeand the exciting partis to use these tools to explain the remarkable phenomenon of self-organization.

McCain said her lab will focus on the device sidethe organ-on-chipand make microfluidic components for growing and studying organoids under more defined conditions.

This will likely improve reproducibility and possibly organoid maturity, which is another major bottleneck, McCain said.

In order to do this, McCains lab will be repurposing a microfluidic device that they previously used to help explanted zebrafish hearts to remain alive longer and regenerate, while also live-imaging the process.

The device, when applied to brain organoids, will constrain the cells in chambers where the team can run experiments through them in a more controlled way, to see if this improves the consistency of the end product.

And we will also be able to image and monitor their reproducibility by putting them in this little device where theyre all growing in the same configuration, McCain said.

Quadrato, an expert in brain organoids, said she was excited about the collaboration, because a multidisciplinary approach was needed to improve the relevance of current organoids.

One way to improve brain organoid-to-organoid reproducibility is to expose them to small molecules to direct differentiation of the stem cells, Quadrato said.

She said that these small molecules unfortunately sometimes have problematic side effects, such as impairing the survival of other non-neural cell types, or skewing tests of potential treatments for brain diseases and disorders.

In our proposal, we suggest an alternative strategy to increase brain organoid reproducibility that does not cause these side effects, and therefore can be used to create organoids to accurately model disease, Quadrato said.

Further information about the project is available from the National Science Foundation.

Here is the original post:
Brain Development and Disorder Research Receives $1.5 Million NSF Boost - USC Viterbi School of Engineering

Cell Biology

Zavala Named One of the Most Inspiring Hispanic/Latinx Scientists in America – CSUN Today

Our aim in assembling these names is to put an end to the harmful myth that there are not enough diverse scientists to give seminars, serve as panelists or fill scientific positions, the authors wrote. We hope it will help to change the perception of what a scientist looks like and makes our collective image more representative of society at large.

Zavala, who has taught at CSUN since 1988, was the first Mexican American woman in the country to earn a Ph.D. in botany. Since coming to CSUN, she has played an integral part in building the national reputation of CSUNsDepartment of Biologyas a place where students, particularly those from underserved communities, thrive and successfully pursue advanced degrees at top-tier research institutions.

She has served as director of CSUNs Maximizing Access to Research Careers Undergraduate Student Training in Academic Research (MARC U-STAR) program since 1990 and Research Initiatives for Scientific Enhancement (RISE) since 1993. Her work as a mentor and advocate for countless students who have gone through these programs earned her recognition from the White House. In 2000, Zavala received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring from former President Bill Clinton. And in 2017,Zavala was named the first Latina Fellow of the American Society of Cell Biologyin its 57-year history.

She also oversees CSUNs work as one of three institutions sharing a first-of-its-kind $3 million, five-year grant from the National Science Foundation to create aHispanic-Serving Institutions(HSI) Resource Hub. The hub is charged with reaching out to colleges and universities across the country to build partnerships that will support STEM education, increase STEM research and education capacity at HSIs, and encourage the implementation of cutting-edge training.

Zavalas research focuses on the manipulation of genes as a way to improve plant productivity by enhancing root growth. She also is studying ways to make beans more nutritious.

In addition to being a Fellow of the American Society of Cell Biology, she is also a Fellow of the American Association for the Advancement of Science and, in 2016, became the first Latina Fellow of the American Society of Plant Biologists.

To be named a Fellow is a recognition of your research and the contributions you have made to a particular field of study, Zavala said in 2017. Its nice recognition from your peers. But I am looking forward to the time when Im not the first, but one of several Latina Fellows.

More:
Zavala Named One of the Most Inspiring Hispanic/Latinx Scientists in America - CSUN Today

Cell Biology

Singapore scientists discover immune pathway that causes immunodeficiency – BSA bureau

The novel pathway can be a target for liver disease and cancer drugs that failed trials due to inflammatory side effects

Scientists from Singapores A*STARs Institute of Molecular and Cell Biology (IMCB), in collaboration with doctors from KK Womens and Childrens Hospital (KKH), have discovered a new immune pathway based on an investigation of severe immunodeficiency caused by a novel mutation in the NFKBIA gene. The findings were published inThe Journal of Clinical Investigation.

A recent investigation with a rare primary immunodeficiency disease involving a two-week old infant with recurrent infections alongside lung, skin and liver damage instigated the discovery. Scientists at A*STAR identified a new genetic variant in NFKBIA that changed the levels of soluble proteins called cytokines, produced by white blood cells to drive inflammation. Abnormally high production of one cytokine, IL-1, was identified as the key derangement. Crucially, the clinical team was able suppress the patients disease by rational administration of the IL-1-blocking drug, Anakinra, based on these scientific results.

The research team, along with Singapore Immunology Network (SIgN) discovered a previously unknown pathway, which controls IL-1 production. By replicating the mutation in pre-clinical and cellular models, experimental results conclusively showed that the patients genetic variant was the cause of IL-1 hyper-production, and hence the disease. These findings have implications for the development of treatments against liver disease and cancer that target this novel pathway.

While other mutations in NFKBIA have been reported before to cause disease, this mutation has never before been identified. It is the only mutation in which hyper-production of IL-1, severe liver cholestasis and systemic inflammation were documented. The research team believes the mutation limits immune responses via the suppression of many pro-inflammatory cytokines. Yet at the same time, it causes over-production of IL-1, leading to liver damage and inflammation. Using this bedside-to-bench approach of identifying the underlying genetic causes of immunodeficiency diseases, previously unknown pathways which control immune responses can be revealed. These then serve as targets for personalised treatment strategies," said Dr John Connolly, a Research Director at IMCB and co-corresponding author of the study.

The research team will further examine which new mediators are responsible for controlling IL-1 production by this genetic variant, given that this regulatory association between the protein encoded in NFKBIA and IL-1 was not observed previously. As this novel pathway has also been a popular target for cancer drugs that failed trials due to inflammatory side effects, the team will investigate whether these new mediators are responsible for the failure of these drugs, and determine if the side effects can be circumvented.

Image Caption:Staining for the signalling protein NFB (green) in skin cells from a healthy individual (left) and the patient (right) after immune stimulation. The patients novel NFKBIA variant impairs entry of NFB into nucleus (blue). This defect led to changes in cytokine production, resulting in both immunodeficiency and multi-organ damage.

Continue reading here:
Singapore scientists discover immune pathway that causes immunodeficiency - BSA bureau

Cell Biology

Global Laser Capture Microdissection Market Will Experience A Noticeable Growth During The Forecast Period 2019-2026||Indivumed GmbH(Germany), AvanSci…

GlobalLaser Capture Microdissection Marketis expected to rise from its initial estimated value of USD 101.3611 million in 2018 to an estimated value of USD 251.14 million by 2026, registering a CAGR of 12.01% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing applications in pharmaceuticals, hospitals and research and development

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-laser-capture-microdissection-market

Few of the major competitors currently working in the Laser Capture Microdissection market areMolecular Machines & Industries(Germany), Danaher (U.S.) , Thermo Fisher Scientific, Inc. (U.S.), ZEISS International(Germany) , DENOVA Sciences Pte Ltd. (Singapore.), Indivumed GmbH(Germany), AvanSci Bio (US), Avant Diagnostics, Inc.(US), Ocimum Biosolutions (India), 3DHISTECH Ltd.( Hungary), Biocompare (Canada)., BioTechniques(UK), MIA Cellavie Inc. (Canada), CaresBio Laboratory LLC (US), Bio-Rad Laboratories, Inc.(US), genedrive plc (UK), Promega Corporation(US), VitroVivo Biotech(India) and Precision MicroFab LLC (US) among others.

Insights of the report

Key Developments in the Market:

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-laser-capture-microdissection-market

Segmentation: Global Laser Capture Microdissection Market

By Product

(Consumables, Reagents and Media, Assay kits, Other consumables, Instruments, Software and Services),

System type

(Ultraviolet lcm, Infrared lcm, Ultraviolet and Infrared lcm, Immunofluorescence lcm),

Application

(research and development, molecular biology, cell biology, forensic science, diagnostics, other applications),

End user

(Academic and Government Research Institutes, Hospitals, Pharmaceutical and Biotechnology companies, Contract Research Organizations (CROS)),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Market Drivers

Market Restraints

To know more about thestudy@https://www.databridgemarketresearch.com/reports/global-laser-capture-microdissection-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

Continue reading here:
Global Laser Capture Microdissection Market Will Experience A Noticeable Growth During The Forecast Period 2019-2026||Indivumed GmbH(Germany), AvanSci...

Cell Biology

Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting – GlobeNewswire

Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation

Company to Host Investor Event on Friday, December 4

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that four oral and eight poster presentations for the Companys induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually from December 5-8, 2020.

Accepted abstracts include a clinical case study of a patient treated with FT596 at the first dose level (30million cells) as a monotherapy in the Companys Phase 1 clinical trial for the treatment of relapsed / refractory B-cell lymphoma (NCT04245722). FT596 is the Companys universal, off-the-shelf, chimeric antigen receptor (CAR) natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary CAR optimized for NK cell biology that targets CD19 (CAR19); a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that enhances antibody-dependent cellular cytotoxicity (ADCC); and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. The accepted abstracts are available online through the ASH conference website (www.hematology.org/Annual-Meeting/Abstracts/).

In addition, the Company plans to host a virtual investor event entitled The Power of hnCD16 to highlight the unique therapeutic features and functionality of its novel hnCD16 Fc receptor, a core component incorporated in its iPSC-derived NK cell product candidates. The Companys hnCD16 Fc receptor is designed to maximize ADCC, a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells, through enhanced binding to tumor-targeting antibodies and prevention of down-regulation commonly observed in cancer patients. Scientists from the Company have shown in a peer-reviewed publication (Blood. 2020;135(6):399-410) that hnCD16 iPSC-derived NK cells, compared to peripheral blood NK cells, elicit a more durable anti-tumor response and extend survival in combination with anti-CD20 monoclonal antibodies in an in vivo xenograft mouse model of human lymphoma.

Oral Presentations

Poster Presentations

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Companys clinical studies and preclinical research and development programs. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, and the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in subject enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development). For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

See the original post:
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting - GlobeNewswire

Cell Biology

Investigations of Deceased COVID-19 Patients Reveal Lung Damage Caused by Persistence of Abnormal Cells – SciTechDaily

Investigations of deceased COVID-19 patients have shed light on possible lung damage caused by the virus.

The study, published today (November 3, 2020) in The Lancets eBioMedicine, by Kings College London in collaboration with University of Trieste and the International Centre for Genetic Engineering and Biology in Italy, shows the unique characteristics to the SARS-CoV-2 virus and may explain why patients suffer from long COVID.

Patients with COVID-19 can experience symptoms such as blood clotting and loss of smell and taste. Some who survive the infection can experience the effects of the disease for months known as long COVID with a feeling of fatigue and lack of breath. There have been a limited number of studies that have analyzed the organs of COVID-19 patients which means the characteristics of the disease are still largely unknown.

Researchers analyzed the organs of 41 patients who died of COVID-19 at the University Hospital of Trieste, Italy, from February to April 2020, at the start of the pandemic. The team took lung, heart, liver, and kidney samples to examine the behavior of the virus.

Findings show extensive lung damage in most cases, with patients experiencing profound disruption of the normal lung structure and the transformation of respiratory tissue into fibrotic material.

Almost 90% of patients showed two additional characteristics that were quite unique to COVID-19 compared to other forms of pneumonia. First, patients showed extensive blood clotting of the lung arteries and veins (thrombosis). Second, several lung cells were abnormally large and had many nuclei, resulting from the fusion of different cells into single large cells. This formation of fused cells (syncytia) is due to the viral spike protein, which the virus uses to enter the cell. When the protein is present on the surface of cells infected by the COVID-19 virus, it stimulates their fusion with other normal lung cells, which can be a cause for inflammation and thrombosis.

Additionally, research showed the long-term persistence of the viral genome in respiratory cells and in cells lining the blood vessels, along with the infected cell syncytia. The presence of these infected cells can cause the major structural changes observed in lungs, which can persist for several weeks or months and could eventually explain long COVID.

The study found no overt signs of viral infection or prolonged inflammation detected in other organs.

Professor Mauro Giacca, at the British Heart Foundation Centre at Kings College London, said: These findings are very exciting. The findings indicate that COVID-19 is not simply a disease caused by the death of virus-infected cells but is likely the consequence of these abnormal cells persisting for long periods inside the lungs.

The team is now actively testing the effect of these abnormal cells on blood clotting and inflammation and are searching for new drugs that can block the viral spike protein which causes cells to fuse.

Reference: Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology by Rossana Bussani, Edoardo Schneider, Lorena Zentilin, Chiara Collesi, Hashim Ali, Luca Braga, Maria Concetta Volpe, Andrea Colliva, Fabrizio Zanconati, Giorgio Berlot and Furio Silvestri, 3 November 2020, eBioMedicine.DOI: 10.1016/j.ebiom.2020.103104

See the original post:
Investigations of Deceased COVID-19 Patients Reveal Lung Damage Caused by Persistence of Abnormal Cells - SciTechDaily